WisdomTree Cloud Computing Fund (WCLD)
- Previous Close
30.45 - Open
30.36 - Bid 30.60 x 200
- Ask 30.73 x 200
- Day's Range
30.22 - 30.73 - 52 Week Range
26.42 - 37.34 - Volume
123,288 - Avg. Volume
169,815 - Net Assets 503.66M
- NAV 30.48
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return -12.88%
- Beta (5Y Monthly) 1.11
- Expense Ratio (net) 0.45%
Under normal circumstances, at least 80% of the fund’s total assets (exclusive of collateral held from securities lending) will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is designed to track the performance of emerging public companies primarily involved in providing cloud computing software and services to their customers. It is non-diversified.
WisdomTree
Fund Family
Technology
Fund Category
503.66M
Net Assets
2019-09-06
Inception Date
Performance Overview: WCLD
Trailing returns as of 6/7/2024. Category is Technology.
People Also Watch
Holdings: WCLD
Top 10 Holdings (20.74% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: WCLD
Fastly Earnings: Atrocious Outlook on Weakness With Major Customers Creates Grave Concerns
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly’s strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2023.
RatingPrice TargetCrispr Earnings: Commercial Launch of Casgevy Is Underway; Positive Outlook and Shares Undervalued
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetFastly Earnings: Atrocious Outlook on Weakness With Major Customers Creates Grave Concerns
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly’s strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2023.
RatingPrice TargetCrispr and Vertex: FDA Approves Gene Editing Drug for Sickle Cell Disease; Positive Long-Term Outlook
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target